DNA GROUP (T.R.) LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.6 ILa | +1.60% |
|
-5.82% | +30.70% |
| 03-19 | Dna Group (T.R.) Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Dna Group (T.R.) Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 0.56 210.27 44.69 | Sales 2023 | 0.31 114.9 24.42 | Capitalization | 77.84M 29.23B 6.21B |
|---|---|---|---|---|---|
| Net income 2022 | -23M -8.64B -1.84B | Net income 2023 | -1M -375M -79.81M | EV / Sales 2022 | 38,063,516 x |
| Net cash position 2022 | 65.73M 24.68B 5.25B | Net cash position 2023 | 66.7M 25.04B 5.32B | EV / Sales 2023 | 36,410,820 x |
| P/E ratio 2022 |
-3.6
x | P/E ratio 2023 |
-63.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.14% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.60% | ||
| 1 week | -5.82% | ||
| Current month | +4.16% | ||
| 1 month | +4.16% | ||
| 3 months | +20.41% | ||
| 6 months | +14.09% | ||
| Current year | +30.70% |
1 week
78.90
88.00
1 month
75.10105.00
Current year
64.20105.00
1 year
56.00110.00
3 years
56.00191.70
5 years
45.00191.70
10 years
45.00454.80
| Managers | Title | Age | Since |
|---|---|---|---|
Ori Altschuler
CEO | Chief Executive Officer | 41 | 17/01/22 |
Klein Tony Hanan
DFI | Director of Finance/CFO | 44 | 14/11/15 |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 26/04/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Orit Stav
BRD | Director/Board Member | 53 | 19/10/22 |
Erez Navon
CHM | Chairman | 50 | 23/02/21 |
Ronen Midbari
BRD | Director/Board Member | 49 | 18/03/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 82.6 | +1.60% | 98,711 |
| 30/04/24 | 81.3 | -5.24% | 338,988 |
| 25/04/24 | 85.8 | -2.17% | 128,607 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 01, 2024 at 03:24 pm
More quotes
DNA Group TR Ltd, former DNA Biomedical Solutions Ltd, is an Israel-based company, which is engaged in the biotechnology sector. The Company's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltdâs proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltdâs drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
| 1st Jan change | Capi. | |
|---|---|---|
| +30.70% | 26.83M | |
| +0.67% | 42.19B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +6.55% | 24.63B | |
| -21.66% | 18.2B | |
| +29.96% | 12.01B | |
| -1.57% | 11.76B | |
| +16.03% | 10.4B | |
| -4.80% | 9.94B |
- Stock Market
- Equities
- DNA Stock
